Immune Cell Composition in Human Non-small Cell Lung Cancer
Branislava Stankovic, Heidi Anine Korsmo Bjørhovde, Renate Skarshaug, Henrik Aamodt, Astri Frafjord, Elisabeth Müller, Clara Hammarström, Kahsai Beraki, Espen S Bækkevold, Per Reidar Woldbæk, Åslaug Helland, Odd Terje Brustugun, Inger Øynebråten, Alexandre Corthay, Branislava Stankovic, Heidi Anine Korsmo Bjørhovde, Renate Skarshaug, Henrik Aamodt, Astri Frafjord, Elisabeth Müller, Clara Hammarström, Kahsai Beraki, Espen S Bækkevold, Per Reidar Woldbæk, Åslaug Helland, Odd Terje Brustugun, Inger Øynebråten, Alexandre Corthay
Abstract
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death in the world. Immunological analysis of the tumor microenvironment (immunoscore) shows great promise for improved prognosis and prediction of response to immunotherapy. However, the exact immune cell composition in NSCLC remains unclear. Here, we used flow cytometry to characterize the immune infiltrate in NSCLC tumors, non-cancerous lung tissue, regional lymph node, and blood. The cellular identity of >95% of all CD45+ immune cells was determined. Thirteen distinct immune cell types were identified in NSCLC tumors. T cells dominated the lung cancer landscape (on average 47% of all CD45+ immune cells). CD4+ T cells were the most abundant T cell population (26%), closely followed by CD8+ T cells (22%). Double negative CD4-CD8- T cells represented a small fraction (1.4%). CD19+ B cells were the second most common immune cell type in NSCLC tumors (16%), and four different B cell sub-populations were identified. Macrophages and natural killer (NK) cells composed 4.7 and 4.5% of the immune cell infiltrate, respectively. Three types of dendritic cells (DCs) were identified (plasmacytoid DCs, CD1c+ DCs, and CD141+ DCs) which together represented 2.1% of all immune cells. Among granulocytes, neutrophils were frequent (8.6%) with a high patient-to-patient variability, while mast cells (1.4%), basophils (0.4%), and eosinophils (0.3%) were less common. Across the cohort of patients, only B cells showed a significantly higher representation in NSCLC tumors compared to the distal lung. In contrast, the percentages of macrophages and NK cells were lower in tumors than in non-cancerous lung tissue. Furthermore, the fraction of macrophages with high HLA-DR expression levels was higher in NSCLC tumors relative to distal lung tissue. To make the method readily accessible, antibody panels and flow cytometry gating strategy used to identify the various immune cells are described in detail. This work should represent a useful resource for the immunomonitoring of patients with NSCLC.
Keywords: NSCLC; flow cytometry; human lung cancer; immunomonitoring; immunoscore; tumor-infiltrating immune cells.
Figures
References
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. (2017) 67:7 10.3322/caac.21387
- Goldstraw P, Ball D, Jett JR, Le Chevalier T, Lim E, Nicholson AG, et al. . Non-small-cell lung cancer. Lancet (2011) 378:1727. 10.1016/S0140-6736(10)62101-0
- Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger K, Yatabe Y, et al. . International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. Proc Am Thorac Soc. (2011) 8:381. 10.1513/pats.201107-042ST
- Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong K-K. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer (2014) 14:535. 10.1038/nrc3775
- Mirsadraee S, Oswal D, Alizadeh Y, Caulo A, van Beek E, Jr. The 7th lung cancer TNM classification and staging system: review of the changes and implications. World J Radiol. (2012) 4:128. 10.4329/wjr.v4.i4.128
- Welsh TJ, Green RH, Richardson D, Waller DA, O'Byrne KJ, Bradding P. Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J Clin Oncol. (2005) 23:8959. 10.1200/JCO.2005.01.4910
- Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. . Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. (2003) 348:203. 10.1056/NEJMoa020177
- Galon J, Pagès F, Marincola FM, Angell HK, Thurin M, Lugli A, et al. . Cancer classification using the Immunoscore: a worldwide task force. J Transl Med. (2012) 10:205. 10.1186/1479-5876-10-205
- Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, et al. . CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. (1998) 58:3491.
- Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, et al. . Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. (2011) 29:1949. 10.1200/JCO.2010.30.5037
- Kilic A, Landreneau RJ, Luketich JD, Pennathur A, Schuchert MJ. Density of tumor-infiltrating lymphocytes correlates with disease recurrence and survival in patients with large non-small-cell lung cancer tumors. J Surg Res. (2011) 167:207. 10.1016/j.jss.2009.08.029
- Horne ZD, Jack R, Gray ZT, Siegfried JM, Wilson DO, Yousem SA, et al. . Increased levels of tumor-infiltrating lymphocytes are associated with improved recurrence-free survival in stage 1A non-small-cell lung cancer. J Surg Res. (2011) 171:1. 10.1016/j.jss.2011.03.068
- Chen X, Wan J, Liu J, Xie W, Diao X, Xu J, et al. . Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients. Lung Cancer (2010) 69:348. 10.1016/j.lungcan.2009.11.013
- Domagala-Kulawik J. The role of the immune system in non-small cell lung carcinoma and potential for therapeutic intervention. Transl Lung Cancer Res. (2015) 4:177. 10.3978/j.issn.2218-6751.2015.01.11
- Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. . Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med. (2012) 366:2443. 10.1056/NEJMoa1200690
- Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. . Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. (2010) 28:3167. 10.1200/JCO.2009.26.7609
- Santarpia M, Giovannetti E, Rolfo C, Karachaliou N, González-Cao M, Altavilla G, et al. . Recent developments in the use of immunotherapy in non-small cell lung cancer. Expert Rev Respir Med. (2016) 10:781. 10.1080/17476348.2016.1182866
- Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. . Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. (2012) 366:2455. 10.1056/NEJMoa1200694
- Donnem T, Kilvaer TK, Andersen S, Richardsen E, Paulsen EE, Hald SM, et al. . Strategies for clinical implementation of TNM-Immunoscore in resected nonsmall-cell lung cancer. Ann Oncol. (2016) 27:225. 10.1093/annonc/mdv560
- Banat GA, Tretyn A, Pullamsetti SS, Wilhelm J, Weigert A, Olesch C, et al. . Immune and inflammatory cell composition of human lung cancer stroma. PLoS ONE (2015) 10:e0139073. 10.1371/journal.pone.0139073
- Johnson SK, Kerr KM, Chapman AD, Kennedy MM, King G, Cockburn JS, et al. . Immune cell infiltrates and prognosis in primary carcinoma of the lung. Lung Cancer (2000) 27:27. 10.1016/S0169-5002(99)00095-1
- Passlick B, Pantel K, Kubuschok B, Angstwurm M, Neher A, Thetter O, et al. . Expression of MHC molecules and ICAM-1 on non-small cell lung carcinomas: association with early lymphatic spread of tumour cells. Eur J Cancer (1996) 32a:141. 10.1016/0959-8049(95)00551-X
- Al-Shibli KI, Donnem T, Al-Saad S, Persson M, Bremnes RM, Busund LT. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res. (2008) 14:5220. 10.1158/1078-0432.CCR-08-0133
- Dieu-Nosjean MC, Antoine M, Danel C, Heudes D, Wislez M, Poulot V, et al. . Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol. (2008) 26:4410. 10.1200/JCO.2007.15.0284
- Ohri CM, Shikotra A, Green RH, Waller DA, Bradding P. Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival. Eur Respir J. (2009) 33:118. 10.1183/09031936.00065708
- Al-Shibli K, Al-Saad S, Donnem T, Persson M, Bremnes RM, Busund LT. The prognostic value of intraepithelial and stromal innate immune system cells in non-small cell lung carcinoma. Histopathology (2009) 55:301. 10.1111/j.1365-2559.2009.03379.x
- Schalper KA, Brown J, Carvajal-Hausdorf D, McLaughlin J, Velcheti V, Syrigos KN, et al. . Objective measurement and clinical significance of TILs in non–small cell lung cancer. JNCI J Natl Cancer Inst. (2015) 107:dju435. 10.1093/jnci/dju435
- Ganesan AP, Johansson M, Ruffell B, Yagui-Beltrán A, Lau J, Jablons DM, et al. . Tumor-infiltrating regulatory T cells inhibit endogenous cytotoxic T cell responses to lung adenocarcinoma. J Immunol. (2013) 191:2009. 10.4049/jimmunol.1301317
- Lizotte PH, Ivanova EV, Awad MM, Jones RE, Keogh L, Liu H, et al. . Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes. JCI Insight (2016) 1:e89014. 10.1172/jci.insight.89014
- Kargl J, Busch SE, Yang GH, Kim KH, Hanke ML, Metz HE, et al. . Neutrophils dominate the immune cell composition in non-small cell lung cancer. Nat Commun. (2017) 8:14381. 10.1038/ncomms14381
- Lardinois D, De Leyn P, Van Schil P, Porta RR, Waller D, Passlick B, et al. . ESTS guidelines for intraoperative lymph node staging in non-small cell lung cancer. Eur J Cardio Thorac Surg. (2006) 30:787. 10.1016/j.ejcts.2006.08.008
- Silina K, Soltermann A, Attar FM, Casanova R, Uckeley ZM, Thut H, et al. . Germinal centers determine the prognostic relevance of tertiary lymphoid structures and are impaired by corticosteroids in lung squamous cell carcinoma. Cancer Res. (2018) 78:1308. 10.1158/0008-5472.CAN-17-1987
- Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature (1999) 401:708. 10.1038/44385
- Geginat J, Lanzavecchia A, Sallusto F. Proliferation and differentiation potential of human CD8+ memory T-cell subsets in response to antigen or homeostatic cytokines. Blood (2003) 101:4260 10.1182/blood-2002-11-3577
- de Chaisemartin L, Goc J, Damotte D, Validire P, Magdeleinat P, Alifano M, et al. . Characterization of chemokines and adhesion molecules associated with T cell presence in tertiary lymphoid structures in human lung cancer. Cancer Res. (2011) 71:6391. 10.1158/0008-5472.CAN-11-0952
- Jackson SM, Wilson PC, James JA, Capra JD. Human B cell subsets. Adv Immunol. (2008) 98:151. 10.1016/S0065-2776(08)00405-7
- Germain C, Gnjatic S, Tamzalit F, Knockaert S, Remark R, Goc J, et al. . Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. Am J Respir Crit Care Med. (2014) 189:832. 10.1164/rccm.201309-1611OC
- Przekopowitz M, Kuppers R, Weniger MA. A large fraction of human tonsillar B cells expressing CD27 are germinal center B cells. Immunol Cell Biol. (2015) 93:429. 10.1038/icb.2015.6
- Clavarino G, Delouche N, Vettier C, Laurin D, Pernollet M, Raskovalova T, et al. . Novel strategy for phenotypic characterization of human B lymphocytes from precursors to effector cells by flow cytometry. PLoS ONE (2016) 11:e0162209. 10.1371/journal.pone.0162209
- Richter L, Landsverk OJB, Atlasy N, Bujko A, Yaqub S, Horneland R, et al. . Transcriptional profiling reveals monocyte-related macrophages phenotypically resembling DC in human intestine. Mucosal Immunol. (2018) 11:1512. 10.1038/s41385-018-0060-1
- Huang A, Zhang B, Wang B, Zhang F, Fan KX, Guo YJ. Increased CD14(+)HLA-DR (-/low) myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients. Cancer Immunol Immunother. (2013) 62:1439. 10.1007/s00262-013-1450-6
- Corthay A, Skovseth DK, Lundin KU, Røsjø E, Omholt H, Hofgaard PO, et al. . Primary antitumor immune response mediated by CD4+ T cells. Immunity (2005) 22:371. 10.1016/j.immuni.2005.02.003
- Corthay A. CD4+ T cells cooperate with macrophages for specific elimination of MHC class II-negative cancer cells. Adv Exp Med Biol. (2007) 590:195. 10.1007/978-0-387-34814-8_14
- Haabeth OA, Lorvik KB, Hammarström C, Donaldson IM, Haraldsen G, Bogen B, et al. . Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer. Nat Commun. (2011) 2:240. 10.1038/ncomms1239
- Müller E, Christopoulos PF, Halder S, Lunde A, Beraki K, Speth M, et al. . Toll-like receptor ligands and interferon-gamma synergize for induction of antitumor M1 macrophages. Front Immunol. (2017) 8:1383. 10.3389/fimmu.2017.01383
- Müller E, Speth M, Christopoulos PF, Lunde A, Avdagic A, Øynebråten I, et al. . Both type I and type II interferons can activate antitumor M1 macrophages when combined with TLR stimulation. Front Immunol. (2018) 9:2520. 10.3389/fimmu.2018.02520
- Basham TY, Merigan TC. Recombinant interferon-gamma increases HLA-DR synthesis and expression. J Immunol. (1983) 130:1492.
- Saikh KU, Dyas B, Kissner T, Ulrich RG. CD56+-T-cell responses to bacterial superantigens and immune recognition of attenuated vaccines. Clin Diagn Lab Immunol. (2003) 10:1065. 10.1128/CDLI.10.6.1065-1073.2003
- Lavin Y, Kobayashi S, Leader A, Amir ED, Elefant N, Bigenwald C, et al. . Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses. Cell (2017) 169:750. 10.1016/j.cell.2017.04.014
- Kataki A, Scheid P, Piet M, Marie B, Martinet N, Martinet Y, et al. . Tumor infiltrating lymphocytes and macrophages have a potential dual role in lung cancer by supporting both host-defense and tumor progression. J Lab Clin Med. (2002) 140:320. 10.1067/mlc.2002.128317
- Zocchi MR, Ferrarini M, Rugarli C. Selective lysis of the autologous tumor by delta TCS1+ gamma/delta+ tumor-infiltrating lymphocytes from human lung carcinomas. Eur J Immunol. (1990) 20:2685. 10.1002/eji.1830201224
- Wakabayashi O, Yamazaki K, Oizumi S, Hommura F, Kinoshita I, Ogura S, et al. CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers. Cancer Sci. (2003) 94:1003 10.1111/j.1349-7006.2003.tb01392.x
- Hiraoka K, Miyamoto M, Cho Y, Suzuoki M, Oshikiri T, Nakakubo Y, et al. . Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer (2006) 94:275. 10.1038/sj.bjc.6602934
- Joly-Battaglini A, Hammarström C, Stankovic B, Aamodt H, Stjärne J, Brustugun OT, et al. . Rituximab efficiently depletes B cells in lung tumors and normal lung tissue. F1000Res (2016) 5:38. 10.12688/f1000research.7599.1
- Gottlin EB, Bentley RC, Campa MJ, Pisetsky DS, Herndon JE, Patz EF. The Association of Intratumoral Germinal Centers with early-stage non-small cell lung cancer. J Thorac Oncol. (2011) 6:1687. 10.1097/JTO.0b013e3182217bec
- Segura E, Touzot M, Bohineust A, Cappuccio A, Chiocchia G, Hosmalin A, et al. . Human inflammatory dendritic cells induce Th17 cell differentiation. Immunity (2013) 38:336. 10.1016/j.immuni.2012.10.018
- Haniffa M, Shin A, Bigley V, McGovern N, Teo P, See P, et al. . Human tissues contain CD141hi cross-presenting dendritic cells with functional homology to mouse CD103+ nonlymphoid dendritic cells. Immunity (2012) 37:60. 10.1016/j.immuni.2012.04.012
- Granot T, Senda T, Carpenter DJ, Matsuoka N, Weiner J, Gordon CL, et al. . Dendritic cells display subset and tissue-specific maturation dynamics over human life. Immunity (2017) 46:504. 10.1016/j.immuni.2017.02.019
- Guilliams M, Ginhoux F, Jakubzick C, Naik SH, Onai N, Schraml BU, et al. . Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny. Nat Rev Immunol. (2014) 14:571. 10.1038/nri3712
- Rajagopal D, Paturel C, Morel Y, Uematsu S, Akira S, Diebold SS. Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists. Blood (2010) 115:1949. 10.1182/blood-2009-08-238543
- Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, et al. . Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med. (2018) 378:1976. 10.1056/NEJMoa1716078
- Carrega P, Morandi B, Costa R, Frumento G, Forte G, Altavilla G, et al. . Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16(-) cells and display an impaired capability to kill tumor cells. Cancer (2008) 112:863. 10.1002/cncr.23239
- Platonova S, Cherfils-Vicini J, Damotte D, Crozet L, Vieillard V, Validire P, et al. . Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res. (2011) 71:5412. 10.1158/0008-5472.CAN-10-4179
- Eruslanov EB, Bhojnagarwala PS, Quatromoni JG, Stephen TL, Ranganathan A, Deshpande C, et al. . Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer. J Clin Invest. (2014) 124:5466. 10.1172/JCI77053
- Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, et al. . Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN. Cancer Cell (2009) 16:183. 10.1016/j.ccr.2009.06.017
- Ilie M, Hofman V, Ortholan C, Bonnetaud C, Coëlle C, Mouroux J, et al. . Predictive clinical outcome of the intratumoral CD66b-positive neutrophil-to-CD8-positive T-cell ratio in patients with resectable nonsmall cell lung cancer. Cancer (2012) 118:1726. 10.1002/cncr.26456
- Carus A, Ladekarl M, Hager H, Pilegaard H, Nielsen PS, Donskov F. Tumor-associated neutrophils and macrophages in non-small cell lung cancer: no immediate impact on patient outcome. Lung Cancer (2013) 81:130. 10.1016/j.lungcan.2013.03.003
Source: PubMed